A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors-Reference-Cited by-同舟云学术

A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors

Published:2020-06-26 Issue:8 Volume:40 Page:345-354
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Wei Xiao‐Li¹^ORCID,Ren Chao¹,Wang Feng‐Hua¹,Zhang Yang¹,Zhao Hong‐Yun¹,Zou Ben‐Yan¹,Wang Zhi‐Qiang¹,Qiu Miao‐Zhen¹^ORCID,Zhang Dong‐Sheng¹,Luo Hui‐Yan¹,Wang Feng¹,Yao Sheng²,Xu Rui‐Hua¹³

Affiliation:

1. Department of Medical OncologyState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineSun Yat‐sen University Cancer Center Guangzhou Guangdong 510060 P. R. China

2. Shanghai Junshi Biosciences Company Limited Shanghai 201203 P. R. China

3. Precision Diagnosis and Treatment for Gastrointestinal CancerChinese Academy of Medical Sciences Guangzhou Guangdong 510060 P. R. China

Funder

National Natural Science Foundation of China

Natural Science Foundation of Guangdong Province

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cac2.12068

Reference27 articles.